{"id":"NCT00876694","sponsor":"Novartis Pharmaceuticals","briefTitle":"Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Efficacy of Indacaterol (300 µg o.d.) Using Salmeterol (50 µg b.i.d.) as an Active Control in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2009-04-07","resultsPosted":"2011-11-08","lastUpdate":"2011-11-08"},"enrollment":186,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"Indacaterol 300 µg","otherNames":[]},{"type":"DRUG","name":"Salmeterol 50 µg","otherNames":[]}],"arms":[{"label":"Indacaterol 300 µg","type":"EXPERIMENTAL"},{"label":"Salmeterol 50 µg","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to collect long term safety data of indacaterol (300 µg o.d.) in Japanese patients with moderate to severe COPD. Data from this study will be used for the registration of indacaterol in Japan.","primaryOutcome":{"measure":"The Number of Participants With a Clinically Notable Pulse Rate During 52 Weeks of Treatment","timeFrame":"52 weeks","effectByArm":[{"arm":"Indacaterol 300 μg","deltaMin":1,"sd":null},{"arm":"Salmeterol 50 μg","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":37,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":125},"commonTop":["Nasopharyngitis","Chronic obstructive pulmonary disease","Cough","Upper respiratory tract infection","Bronchitis"]}}